Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics

Reduced expression of BRCA1 has been reported in sporadic breast cancer, although the mechanisms underlying this phenomenon remain unclear. Abnormal methylation leading to silencing of tumour suppressor genes has been implicated in tumorigenesis in a wide range of sporadic cancers. Therefore, we sought to determine the frequency of methylation within the BRCA1 promoter region in a large group of sporadic invasive breast (n=96) and ovarian (n=43) carcinomas using Southern analyses. Overall, methylation was detected in 11% of breast cancer cases and in 5% of ovarian tumours. Methylation of the BRCA1 promoter region was strongly correlated with lack of estrogen and progesterone receptor expression. It is clear from the frequency of abnormal methylation of the BRCA1 promoter region, that this cannot be the sole mechanism mediating the reduced expression of BRCA1 that has previously been reported to occur in the majority of invasive sporadic breast tumours. Nevertheless this study suggests that abnormal methylation of the BRCA1 promoter may be important in tumorigenesis in a subset of sporadic breast and ovarian cancers.

[1]  G. Sourvinos,et al.  Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. , 1998, Biochemical and biophysical research communications.

[2]  Peter W. Laird,et al.  THE ROLE OF DNA METHYLATION IN CANCER GENETICS AND EPIGENETICS , 1996 .

[3]  R. Lidereau,et al.  Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted. , 1993, Cancer research.

[4]  N. Blin,et al.  A general method for isolation of high molecular weight DNA from eukaryotes. , 1976, Nucleic acids research.

[5]  A. Bird,et al.  Sp1 sites in the mouse aprt gene promoter are required to prevent methylation of the CpG island. , 1994, Genes & development.

[6]  T. Dryja,et al.  Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. , 1991, American journal of human genetics.

[7]  S. Baylin,et al.  Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells. , 1994, Cancer research.

[8]  A. Jeffreys,et al.  A somatic BRCA1 mutation in an ovarian tumour , 1995, Nature Genetics.

[9]  J. Herman,et al.  Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. , 1996, Cancer research.

[10]  D. Barnes,et al.  Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. , 1996, British Journal of Cancer.

[11]  M. King,et al.  Growth retardation and tumour inhibition by BRCA1 , 1996, Nature Genetics.

[12]  David L. Page,et al.  Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression , 1995, Nature Genetics.

[13]  S. Baylin,et al.  Demethylation of the estrogen receptor gene in estrogen receptor-negative breast cancer cells can reactivate estrogen receptor gene expression. , 1995, Cancer research.

[14]  V. Kosma,et al.  Hypermethylation of the APC (adenomatous Polyposis Coli) gene promoter region in human colorectal carcinoma , 1997, International journal of cancer.

[15]  F. O'Malley,et al.  CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site , 1998, Oncogene.

[16]  M. Carcangiu,et al.  Allelic loss in ovarian cancer , 1993, International journal of cancer.

[17]  L. Hood,et al.  Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. , 1996, Genome research.

[18]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[19]  D. Lubahn,et al.  Identification of DNA methylation markers for human breast carcinomas using the methylation-sensitive restriction fingerprinting technique. , 1997, Cancer research.

[20]  Chun-Fang Xu,et al.  Distinct transcription start sites generate two forms of BRCA1 mRNA. , 1995, Human molecular genetics.

[21]  D. Easton,et al.  Risks of cancer in BRCA1-mutation carriers , 1994, The Lancet.

[22]  Y. Nakamura,et al.  Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21.3 often and commonly deleted in tumors. , 1993, Cancer research.

[23]  Nigel Kirkham,et al.  Progress in Pathology , 1995 .

[24]  J. Wahlfors,et al.  Hypermethylation of calcitonin gene regulatory sequences in human breast cancer as revealed by genomic sequencing , 1996, International journal of cancer.

[25]  Chun-Fang Xu,et al.  Complex Regulation of the BRCA1 Gene* , 1997, The Journal of Biological Chemistry.

[26]  B. Katzenellenbogen,et al.  Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. , 1988, Molecular endocrinology.

[27]  F. Collins,et al.  Somatic mutations in the BRCA1 gene in sporadic ovarian tumours , 1995, Nature Genetics.

[28]  J. Herman,et al.  Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Herman,et al.  5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers , 1995, Nature Medicine.

[30]  Z. Siegfried,et al.  Spl elements protect a CpG island from de novo methylation , 1994, Nature.